Top Markets
Coin of the day
DelMar Pharmaceuticals, Inc. DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc.

DMPWW
Rang in aandelen #42376
Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc.... Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc. until its rebranding in August 2020, operates as a clinical-stage pharmaceutical firm. Headquartered in San Diego, California, and established in 2009, the company is committed to advancing and bringing to market anti-cancer treatments for patients. Its development pipeline includes two advanced therapeutic candidates. One is VAL-083, a DNA-targeting agent poised for Phase III trials, designed to combat various drug-resistant solid tumors such as glioblastoma multiforme, ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The other is REM-001, a late-stage photodynamic therapy intended for conditions like cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and addressing access graft failure in hemodialysis patients. Kintara Therapeutics also maintains a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and commercialization of VAL-083 within the Chinese market.
Aandeelprijs
$0.005
Laatst gesynchroniseerd: 2024-06-20
Marktkapitalisatie
$1.74K
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel DelMar Pharmaceuticals, Inc. (DMPWW)

Categorie

EPS voor DelMar Pharmaceuticals, Inc. (DMPWW)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van DelMar Pharmaceuticals, Inc. is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van DelMar Pharmaceuticals, Inc. van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten